EVERGRAF 0.25 TABS 10'S

About

EVERGRAF 0.25 TABS 10'S contains Everolimus, an immunosuppressant and antineoplastic agent belonging to the class of mTOR (mammalian target of rapamycin) inhibitors. Everolimus works by forming a complex with FKBP-12, which then inhibits mTOR, a key regulatory kinase involved in cell growth, proliferation, and angiogenesis. In the context of organ transplantation, this inhibition suppresses T-cell activation and proliferation, thereby preventing acute organ rejection. In oncology, its action on mTOR pathways helps to reduce tumor cell proliferation, angiogenesis, and glucose uptake, making it effective in treating certain types of cancer. Its dual role as an immunosuppressant and an anticancer agent highlights its versatility in clinical practice. Careful monitoring of drug levels and adverse effects is crucial due to its narrow therapeutic index and potential for significant side effects.

Uses

• Prevention of organ transplant rejection
• Treatment of advanced renal cell carcinoma
• Management of progressive neuroendocrine tumors
• Therapy for subependymal giant cell astrocytoma (SEGA)

Directions For Use

Take orally once daily at the same time each day, consistently with or without food. Do not crush or chew the tablets.

Benefits

• Effectively prevents organ transplant rejection
• Demonstrates efficacy in specific cancer types
• Reduces tumor growth and progression
• Improves progression-free survival in oncology patients
• Allows for steroid-sparing regimens in transplant patients
• Offers a targeted therapeutic approach

Side Effects

• Mouth ulcers or stomatitis
• Rash and skin reactions
• Diarrhea or abdominal pain
• Fatigue and weakness
• Peripheral edema (swelling)
• Hyperlipidemia (high cholesterol)
• Hyperglycemia (high blood sugar)
• Non-infectious pneumonitis
• Increased risk of infections
• Anemia and thrombocytopenia
• Proteinuria (protein in urine)
• Hypertension (high blood pressure)

Safety Measures

• Alcohol - Limit or avoid alcohol consumption as it may exacerbate liver strain and interact with immunosuppression.
• Pregnancy - Contraindicated. Everolimus is teratogenic and can cause fetal harm. Use effective contraception during and after treatment.
• Breastfeeding - Contraindicated. Everolimus is excreted in breast milk and can cause serious adverse effects in the infant.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustments are required based on liver function.
• Kidney - Monitor renal function closely. Everolimus may cause proteinuria and can impact kidney function, especially in transplant patients.
• Lung - Risk of non-infectious pneumonitis. Monitor for respiratory symptoms like cough, dyspnea, or fever; dose reduction or discontinuation may be necessary.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.